Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

This is not an experiment but a systematic review and clinical practice guideline update. The authors examined published evidence from 2017–2021 on how to manage immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICPis). The "intervention" being evaluated was not a drug but a management strategy: a graded approach to handling side effects based on severity (Grade 1–4, using the Common Terminology Criteria for Adverse Events v5.0). The "comparator" was implicit—standard care or no standardised guidance. The primary outcome was safe and effective management of irAEs, measured by resolution of symptoms, avoidance of life-threatening complications, and ability to continue cancer treatment when possible.

The guideline is based on a systematic review of 175 studies. The target population for the recommendations is adult patients with cancer receiving immune checkpoint inhibitor therapy alone (not in combination with chemotherapy). The studies included patients with various solid-organ and haematologic malignancies. No single sample size applies because this is a synthesis across multiple studies. The expert panel comprised 28 members from medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, haematology, emergency medicine, nursing, trial methodology, and patient advocacy.

The guideline uses the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 to grade toxicity severity:

• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
• Grade 2: Moderate; minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
• Grade 3: Severe or medically significant but not immediately life-threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting self-care activities of daily living.
• Grade 4: Life-threatening consequences; urgent intervention indicated.
• Grade 5: Death related to adverse event.

Organ-specific toxicities were assessed using standard clinical, laboratory, and imaging methods: skin exams for dermatologic toxicity, liver function tests for hepatitis, thyroid function tests for endocrinopathies, pulmonary function tests and CT imaging for pneumonitis, colonoscopy with biopsy for colitis, and cardiac biomarkers and echocardiography for myocarditis.

Study design: Systematic review with expert consensus guideline. The panel conducted a literature search of PubMed on May 15, 2020, with an update on March 2, 2021. They identified 175 eligible studies published between 2017 and 2021.

Inclusion criteria: Adult patients with cancer receiving ICPi monotherapy (not combined with chemotherapy). Studies had to address steroids, immunosuppressive therapy, dose modification, organ-specific management, hospitalisation, or discontinuation of therapy.

Exclusion criteria: Investigational agents not FDA-approved, clinical trial protocols, and paediatric-only studies.

Statistical approach: No meta-analysis was performed. Because of the "paucity of high-quality evidence," all recommendations are based on expert consensus rather than formal statistical synthesis. The panel used the Guidelines Into Decision Support methodology to craft recommendations.

What this design can and cannot prove:

This design can synthesise available evidence across multiple organ systems and cancer types, identify gaps in the literature, and produce standardised management recommendations where none existed. It can provide a framework for clinicians facing common clinical scenarios.

This design cannot prove that any specific management strategy is superior to another because there were no randomised controlled trials comparing different management approaches. The recommendations are expert opinion, not evidence-based in the traditional sense. The guideline explicitly states that "recommendations are based on expert consensus" due to the lack of high-quality evidence. This means the recommendations may change as better evidence emerges. The design also cannot determine optimal corticosteroid dosing or tapering schedules because comparative studies are lacking.

Major methodological weaknesses:

1. No formal meta-analysis or quantitative synthesis of effect sizes.
2. No systematic assessment of publication bias.
3. The literature search was limited to PubMed only.
4. Only English-language studies were included.
5. Studies involving combination therapies (ICPi plus chemotherapy, targeted therapy, or radiation) were excluded, limiting generalisability to modern treatment regimens.
6. The guideline is funded by ASCO, a professional organisation with potential conflicts of interest regarding immunotherapy promotion.
7. Many recommendations are based on single-arm case series or retrospective data rather than randomised trials.

General incidence and timing:

• Patients receiving anti-PD-1 or PD-L1 antibodies have a lower incidence of any-grade irAEs than those treated with anti-CTLA-4 agents.
• Combination therapy (anti-PD-1/PD-L1 plus anti-CTLA-4) increases the incidence, severity, and speed of onset of irAEs.
• Median onset of irAEs is approximately 40 days, but onset can range from days to up to 26 weeks after starting treatment.

Graded management approach (the core recommendation):

• Grade 1 toxicities: Continue ICPi therapy with close monitoring. Exceptions: some neurologic, haematologic, and cardiac toxicities may warrant holding treatment even at Grade 1.
• Grade 2 toxicities: Consider holding ICPis. Resume when symptoms and/or laboratory values revert to Grade 1 or lower. Corticosteroids may be administered at an initial dose of 0.5–1 mg/kg/day of prednisone or equivalent.
• Grade 3 toxicities: Hold ICPis. Initiate high-dose corticosteroids (prednisone 1–2 mg/kg/day or equivalent). Taper corticosteroids over at least 4–6 weeks. If symptoms do not improve within 48–72 hours of high-dose steroids, infliximab may be offered for some toxicities (e.g., colitis).
• Grade 4 toxicities: Permanently discontinue ICPis, except for endocrinopathies that have been controlled by hormone replacement therapy.

Rechallenge recommendations:

• When symptoms revert to Grade 1 or lower, rechallenging with ICPis may be offered.
• Caution is advised, especially in patients with early-onset irAEs.
• Dose adjustments are not recommended.
• For patients who developed toxicity on combination therapy (anti-CTLA-4 plus anti-PD-1/PD-L1), rechallenge with PD-1/PD-L1 monotherapy may be offered once recovered to Grade 1 or lower.

Organ-specific findings (selected examples):

• Dermatologic toxicity: Most common irAE. Grade 1–2: topical corticosteroids and antihistamines. Grade 3: hold ICPi, oral prednisone 0.5–1 mg/kg/day.
• Colitis/diarrhoea: Grade 1: continue ICPi, symptomatic management. Grade 2: hold ICPi, oral prednisone 0.5–1 mg/kg/day. Grade 3: hold ICPi, IV methylprednisolone 1–2 mg/kg/day, consider infliximab if no improvement in 48–72 hours.
• Pneumonitis: Grade 1: consider holding ICPi, monitor closely. Grade 2: hold ICPi, oral prednisone 1–2 mg/kg/day. Grade 3–4: permanently discontinue ICPi, hospitalise, IV methylprednisolone 1–2 mg/kg/day.
• Myocarditis: Grade 1–4: permanently discontinue ICPi, hospitalise, high-dose corticosteroids (methylprednisolone 1 g/day IV for 3–5 days then taper). This is one of the most dangerous irAEs with high mortality.
• Endocrinopathies (thyroiditis, hypophysitis, adrenal insufficiency): Hormone replacement therapy as needed. ICPi may be continued if symptoms are controlled with replacement hormones. Grade 4 endocrinopathies do not require permanent discontinuation if controlled.
• Hepatitis: Grade 1: continue ICPi. Grade 2: hold ICPi, oral prednisone 0.5–1 mg/kg/day. Grade 3–4: permanently discontinue ICPi, IV methylprednisolone 1–2 mg/kg/day.

Because this is a consensus guideline rather than a single study with effect sizes, the "effect magnitude" refers to the expected clinical impact of following these recommendations:

• For Grade 1 toxicities, continuing ICPi means patients avoid unnecessary treatment interruptions that could reduce cancer control. The risk of progression from mild to severe toxicity with close monitoring is estimated to be low, though exact numbers are not provided.
• For Grade 3 toxicities, high-dose corticosteroids (prednisone 1–2 mg/kg/day) typically lead to symptom improvement within 48–72 hours in most patients, though the guideline does not report exact response rates.
• For corticosteroid-refractory colitis, infliximab (5 mg/kg single dose) leads to clinical response in approximately 70–80% of cases based on the underlying literature, though the guideline does not cite this specific number.
• Permanent discontinuation of ICPis for Grade 4 toxicities means patients lose access to potentially life-saving cancer therapy, but the alternative—continuing treatment—carries a risk of fatal complications. Myocarditis, for example, has a mortality rate of approximately 50% in published case series.

What the authors acknowledge:

• "Paucity of high-quality evidence" for most recommendations.
• All recommendations are "consensus based with benefits outweighing harms" rather than evidence-based.
• The guideline does not cover combination therapies (ICPi plus chemotherapy, targeted therapy, or radiation), which are increasingly common in clinical practice.
• The guideline does not address management of toxicities from novel agents or combination regimens still under investigation.

What a critical reader would note:

• No randomised controlled trials compare different management strategies (e.g., different corticosteroid doses, different tapering schedules, different immunosuppressive agents).
• The literature search was limited to PubMed and English-language studies, potentially missing relevant non-English research or grey literature.
• The guideline was funded by ASCO, which has an institutional interest in promoting immunotherapy use.
• Many panel members have financial conflicts of interest (pharmaceutical company consulting, research funding) that are disclosed but not quantified in terms of potential bias.
• The recommendations are based on expert opinion, which can be influenced by prevailing clinical practice rather than objective evidence.
• The guideline does not provide specific numbers for how often each grade of toxicity occurs, making it difficult to assess baseline risk.
• No discussion of patient preferences or shared decision-making in the management algorithm.
• The tapering schedule for corticosteroids (at least 4–6 weeks) is arbitrary and not based on comparative data.
• The guideline does not address long-term outcomes of patients who develop irAEs, such as whether permanent discontinuation affects cancer survival.

For someone running their own n=1 experiment:

This guideline is designed for clinicians managing cancer patients on immunotherapy. However, if you are considering a self-experiment involving immune modulation (e.g., supplements, dietary interventions, or experimental treatments that affect the immune system), the graded toxicity management framework is useful as a safety protocol.

What to test:

• If you are experimenting with any intervention that modulates immune function (e.g., high-dose vitamin D, zinc, beta-glucans, or other immunostimulants), use the CTCAE grading system to monitor for potential immune-related side effects.
• Specifically track: skin changes (rash, itching), gastrointestinal symptoms (diarrhoea, abdominal pain), respiratory symptoms (cough, shortness of breath), fatigue, fever, and any new neurological symptoms.

Minimum meaningful duration:

• The guideline notes that irAEs can occur from days to 26 weeks after starting an immune-modulating agent, with median onset around 40 days. For a self-experiment, a minimum monitoring period of 8–12 weeks is reasonable to capture most potential reactions.
• If you are testing a short-term intervention (e.g., a 2-week supplement course), monitor for at least 4 weeks after the intervention ends, as delayed reactions are possible.

What to measure (specific metrics):

• Daily symptom diary: Rate each symptom on a 0–4 scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening) using the CTCAE framework.
• Objective measures: Body temperature (daily), stool frequency and consistency (Bristol Stool Scale), skin photos (for rashes), peak flow meter readings (for respiratory symptoms), and blood pressure.
• Laboratory tests (if accessible): Complete blood count, comprehensive metabolic panel (including liver function tests), thyroid-stimulating hormone (TSH), and C-reactive protein (CRP) at baseline and weekly during the experiment.
• Functional status: Record ability to perform daily activities (instrumental activities of daily living) on a 0–4 scale.

Key confounds to control for:

• Concurrent medications: Any NSAIDs, antibiotics, or other drugs that affect immune function must be held constant or documented.
• Infections: Viral or bacterial infections can mimic irAEs. Monitor for fever, localising symptoms, and consider testing if symptoms develop.
• Diet and exercise: Both can affect immune function. Keep these consistent during the experiment.
• Stress and sleep: Both modulate immune responses. Track perceived stress (e.g., Perceived Stress Scale) and sleep quality (e.g., sleep diary or actigraphy).
• Placebo effect: If possible, use a blinded design (e.g., have someone else prepare your doses so you don't know if you're taking the active agent or placebo).

What a positive result would look like:

• A positive result for safety would be: No symptoms above Grade 1 (mild) throughout the experiment and for 4 weeks after discontinuation.
• A positive result for efficacy (if testing an immune-modulating intervention) would be: Measurable improvement in a specific outcome (e.g., reduced frequency of infections, improved energy levels, better wound healing) without any Grade 2 or higher adverse events.
• A negative result requiring immediate action: Any symptom reaching Grade 2 (moderate, limiting daily activities) should prompt you to stop the intervention and seek medical advice. Grade 3 or 4 symptoms require emergency medical attention.

Specific safety thresholds for stopping your experiment:

• Fever >38.5°C for more than 24 hours without clear cause.
• Diarrhoea >6 stools/day above baseline, or any bloody diarrhoea.
• Rash covering >30% of body surface area or with blistering.
• Shortness of breath at rest or with minimal exertion.
• Jaundice (yellowing of skin or eyes) or dark urine.
• New neurological symptoms (weakness, numbness, vision changes, confusion).
• Heart palpitations, chest pain, or unexplained rapid heart rate.

Important caveat: This guideline is designed for cancer patients on immunotherapy, not for healthy individuals experimenting with immune-modulating substances. The risk-benefit calculation is entirely different. If you are not being treated for cancer, the threshold for stopping an experiment should be much lower—any persistent symptom above Grade 1 should prompt discontinuation and medical evaluation. Do not attempt to replicate cancer immunotherapy protocols at home. The drugs discussed in this guideline (ipilimumab, nivolumab, pembrolizumab) are prescription-only and carry significant risks including death. This framework is provided for safety monitoring of lower-risk interventions only.